Ara-C affects formation of cancer cell DNA synthesome replication intermediates

• Published in: Cancer chemotherapy and pharmacology Vol. 45; no. 4; pp. 312 - 319
• Main Authors: ABDEL-AZIZ, W, JIANG, H.-Y, HICKEY, R. J, MALKAS, L. H
• Format: Journal Article
• Language: English
• Published: Berlin Springer 2000
• Subjects: Antigens, Polyomavirus Transforming - metabolism; Antimetabolites, Antineoplastic - pharmacology; Antineoplastic agents; Arabinofuranosylcytosine Triphosphate - pharmacology; Biological and medical sciences; Breast Neoplasms - metabolism; Cell Division - drug effects; Cytarabine - pharmacology; DNA Polymerase I - biosynthesis; DNA Polymerase III - biosynthesis; DNA Replication - drug effects; DNA, Neoplasm - biosynthesis; General aspects; Humans; Medical sciences; Pharmacology. Drug treatments; Replicon - drug effects; Tumor Cells, Cultured; Antineoplastic agent; Human; DNA synthesis; Malignant tumor; In vitro; Mammary gland diseases; Cytarabine; Antimetabolic; DNA; Established cell line; Replication; Mammary gland; Mechanism of action; Pyrimidine nucleoside
• ISSN: 0344-5704; 1432-0843
• DOI: 10.1007/s002800050046

An intact and fully functional multiprotein DNA replication complex (DNA synthesome) from human as well as from murine mammary carcinoma cells was first isolated and characterized in our laboratory. The human cell synthesome supports the in vitro origin-specific simian virus 40 (SV40) DNA replication reaction in the presence of the viral large T-antigen using a semiconservative mechanism and has been shown to contain all the proteins and enzymes required to support DNA synthesis. We are currently using the DNA synthesome as a unique model for analyzing the mechanism of action of anticancer drugs affecting DNA replication. The purpose of this study was to further investigate the mechanism of action of ara-C using the DNA synthesome isolated from the human breast cancer cell line MDA MB-468. Synthesome-mediated SV40 DNA replication was performed in the presence of various concentrations of ara-CTP (the active metabolite of ara-C) and the types of daughter DNA molecules produced were analyzed lusing neutral and alkaline gel electrophoresis. We also examined the effect of ara-C on intact MDA MB-468 cell DNA synthesis and on cell proliferation. In addition, we studied the effect of ara-CTP on the activity of some of the synthesome target proteins (the DNA polymerases alpha and delta). Full-length daughter DNA molecules were obtained in the presence of low concentrations of ara-CTP while at higher concentrations, there was an inhibition of full-length daughter DNA synthesis. The findings suggest that specifically the initiation phase of DNA synthesis was inhibited by ara-CTP since the production of the short Okazaki fragments was suppressed at all concentrations of the drug above 10 microM. In addition, it was found that the IC50 of ara-CTP for inhibition of synthesome-mediated in vitro DNA replication was comparable to that required to inhibit intact cell DNA synthesis. Further experimentation has shown that ara-CTP preferentially inhibits the activity of the synthesome-associated DNA polymerase alpha enzyme while the DNA polymerase delta seems to be resistant to the inhibitory effect of that drug. Our results indicate that ara-C's action on DNA replication is mediated primarily through DNA polymerase alpha and suggest that this enzyme plays a key role in DNA synthetic initiation events. The results also provide definitive support for the use of the DNA synthesome as a unique and powerful model for analyzing the mechanism of action of anticancer drugs which directly affect DNA replication.